ID3 promotes homologous recombination via non-transcriptional and transcriptional mechanisms and its loss confers sensitivity to PARP inhibition

Author:

Bakr Ali1ORCID,Hey Joschka12,Sigismondo Gianluca3,Liu Chun-Shan1,Sadik Ahmed4,Goyal Ashish1,Cross Alice15,Iyer Ramya Lakshmana1,Müller Patrick1,Trauernicht Max1,Breuer Kersten1,Lutsik Pavlo1,Opitz Christiane A46,Krijgsveld Jeroen37,Weichenhan Dieter1,Plass Christoph18,Popanda Odilia1,Schmezer Peter1

Affiliation:

1. Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany

2. Heidelberg University, Faculty of Biosciences, 69120 Heidelberg, Germany

3. Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), INF581, 69120 Heidelberg, Germany

4. DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

5. Imperial College London, London, SW7 2AZ, UK

6. Neurology Clinic and National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany

7. Heidelberg University, Medical Faculty, INF672, 69120, Heidelberg, Germany

8. German Cancer Consortium (DKTK), INF280, 69120 Heidelberg, Germany

Abstract

Abstract The inhibitor of DNA-binding 3 (ID3) is a transcriptional regulator that limits interaction of basic helix-loop-helix transcription factors with their target DNA sequences. We previously reported that ID3 loss is associated with mutational signatures linked to DNA repair defects. Here we demonstrate that ID3 exhibits a dual role to promote DNA double-strand break (DSB) repair, particularly homologous recombination (HR). ID3 interacts with the MRN complex and RECQL helicase to activate DSB repair and it facilitates RAD51 loading and downstream steps of HR. In addition, ID3 promotes the expression of HR genes in response to ionizing radiation by regulating both chromatin accessibility and activity of the transcription factor E2F1. Consistently, analyses of TCGA cancer patient data demonstrate that low ID3 expression is associated with impaired HR. The loss of ID3 leads to sensitivity of tumor cells to PARP inhibition, offering new therapeutic opportunities in ID3-deficient tumors.

Funder

German Cancer Research Center

German Research Foundation

Helmholtz Association Grant

Publisher

Oxford University Press (OUP)

Subject

Genetics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3